CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more
CStone Pharmaceuticals (CSPHF) - Total Liabilities
Latest total liabilities as of June 2025: $876.86 Million USD
Based on the latest financial reports, CStone Pharmaceuticals (CSPHF) has total liabilities worth $876.86 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CStone Pharmaceuticals - Total Liabilities Trend (2016–2024)
This chart illustrates how CStone Pharmaceuticals's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CStone Pharmaceuticals Competitors by Total Liabilities
The table below lists competitors of CStone Pharmaceuticals ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SunOpta Inc.
NASDAQ:STKL
|
USA | $516.07 Million |
|
Canada Goose Holdings Inc
NYSE:GOOS
|
USA | $1.21 Billion |
|
Gravita India Limited
NSE:GRAVITA
|
India | ₹6.06 Billion |
|
Jiangsu Yangdian Science & Technology Co. Ltd.
SHE:301012
|
China | CN¥388.53 Million |
|
Boss Resources Ltd
OTCQX:BQSSF
|
USA | $44.54 Million |
|
V V Food & Beverage Co Ltd
SHG:600300
|
China | CN¥1.11 Billion |
|
Lake Materials Co. Ltd.
KQ:281740
|
Korea | ₩228.38 Billion |
|
Aavas Financiers Limited
NSE:AAVAS
|
India | ₹147.61 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down CStone Pharmaceuticals's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.78 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CStone Pharmaceuticals's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CStone Pharmaceuticals (2016–2024)
The table below shows the annual total liabilities of CStone Pharmaceuticals from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.03 Billion | -14.57% |
| 2023-12-31 | $1.21 Billion | +1.35% |
| 2022-12-31 | $1.19 Billion | +11.71% |
| 2021-12-31 | $1.06 Billion | +31.69% |
| 2020-12-31 | $808.29 Million | +72.32% |
| 2019-12-31 | $469.06 Million | -58.00% |
| 2018-12-31 | $1.12 Billion | +886.32% |
| 2017-12-31 | $113.23 Million | +91.32% |
| 2016-12-31 | $59.18 Million | -- |